Home Overview Press Room Blog Publications For Students about us
Search

Biotech & Pharma : Displaying 11-20 of 2595


Lawmakers try to fix a side effect of reducing drug and theft crimes: Not enough DNA samples for cold casesby Jazmine UlloaLos Angeles TimesDecember 22nd, 2016A California bill would expand the state's DNA database, raising serious concerns about privacy and disproportionately targeting blacks and Latinos.
‘Gene drive’ moratorium shot down at UN biodiversity meetingby Ewen CallawayNatureDecember 21st, 2016Environmental activists’ appeals for a freeze on gene-drive field trials, and on some lab research, are likely to resurface in the future.
Why tech offers better fertility benefits than other industries[cites CGS's Marcy Darnovsky]by Alison DeNiscoTech RepublicDecember 21st, 2016The benefits are part of the current talent war for engineers and other professionals. Tech workers should be cautious about using the procedures.
Four Steps Forward, One Leap Back on Global Governance of Synthetic Biologyby ETC GroupETC GroupDecember 19th, 2016196 countries meeting at the UN Convention on Biodiversity grappled with how synthetic biology and other risky technologies threaten biodiversity, local economies, and the rights of farmers and Indigenous Peoples.
Gene-editing firms form patent alliance against Editas, Broadby Max StendahlBoston Business JournalDecember 16th, 2016The announcement formalizes a legal coordination and cost-sharing arrangement among four biotech companies.
Biopolitical News of 2016by Pete Shanks, Leah Lowthorp & Marcy DarnovskyBiopolitical TimesDecember 13th, 2016We highlight 2016’s trends in and top news stories about human biotech developments.
With 21st Century Cures Act, the Future of Regenerative Medicine Is “Inject and See”by Megan MoltenWiredDecember 13th, 2016Critics say it’s deregulation in sheep’s clothing — and worry that both science and patients will suffer.
Why the hype around medical genetics is a public enemyby Nathaniel ComfortAeonDecember 12th, 2016The progress of science is the steady realisation of how little we actually know. The more we, the public, understand that, the more we will see through the hype.
Trump is considering a radical to lead FDA. That’s dangerous for public healthby Ed SilvermanSTATDecember 12th, 2016Imagine being prescribed a medicine when no one has a clue if it will work — because the government never required it to be tested for effectiveness.
Historians seek reparations for Californians forcibly sterilizedby Ronnie CohenReuters HealthDecember 12th, 2016Alexandra Stern and colleagues investigated over 20,000 documents from the state's eugenics program. Many victims are alive today; California, like other states, should offer them financial compensation.
Displaying 11-20 of 2595  
< Prev  Next >> 
« First Page Last Page » 
« Show Complete List » 


ESPAÑOL | PORTUGUÊS | Русский

home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1122 University Ave, Suite 100, Berkeley, CA 94702 • • (p) 1.510.665.7760 • (F) 1.510.665.8760